These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 19258598)
1. The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Novak U; Rinaldi A; Kwee I; Nandula SV; Rancoita PM; Compagno M; Cerri M; Rossi D; Murty VV; Zucca E; Gaidano G; Dalla-Favera R; Pasqualucci L; Bhagat G; Bertoni F Blood; 2009 May; 113(20):4918-21. PubMed ID: 19258598 [TBL] [Abstract][Full Text] [Related]
2. A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders/lymphomas. Ando M; Sato Y; Takata K; Nomoto J; Nakamura S; Ohshima K; Takeuchi T; Orita Y; Kobayashi Y; Yoshino T PLoS One; 2013; 8(2):e56741. PubMed ID: 23418597 [TBL] [Abstract][Full Text] [Related]
3. TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma. Honma K; Tsuzuki S; Nakagawa M; Karnan S; Aizawa Y; Kim WS; Kim YD; Ko YH; Seto M Genes Chromosomes Cancer; 2008 Jan; 47(1):1-7. PubMed ID: 17886247 [TBL] [Abstract][Full Text] [Related]
4. Mutation analysis of NF-κB signal pathway-related genes in ocular MALT lymphoma. Liu F; Karube K; Kato H; Arita K; Yoshida N; Yamamoto K; Tsuzuki S; Kim W; Ko YH; Seto M Int J Clin Exp Pathol; 2012; 5(5):436-41. PubMed ID: 22808296 [TBL] [Abstract][Full Text] [Related]
5. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Honma K; Tsuzuki S; Nakagawa M; Tagawa H; Nakamura S; Morishima Y; Seto M Blood; 2009 Sep; 114(12):2467-75. PubMed ID: 19608751 [TBL] [Abstract][Full Text] [Related]
6. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. Schmitz R; Hansmann ML; Bohle V; Martin-Subero JI; Hartmann S; Mechtersheimer G; Klapper W; Vater I; Giefing M; Gesk S; Stanelle J; Siebert R; Küppers R J Exp Med; 2009 May; 206(5):981-9. PubMed ID: 19380639 [TBL] [Abstract][Full Text] [Related]
7. A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands. Chanudet E; Ye H; Ferry J; Bacon CM; Adam P; Müller-Hermelink HK; Radford J; Pileri SA; Ichimura K; Collins VP; Hamoudi RA; Nicholson AG; Wotherspoon AC; Isaacson PG; Du MQ J Pathol; 2009 Feb; 217(3):420-30. PubMed ID: 19006194 [TBL] [Abstract][Full Text] [Related]
8. Mutation analysis of the TNFAIP3 (A20) tumor suppressor gene in CLL. Philipp C; Edelmann J; Bühler A; Winkler D; Stilgenbauer S; Küppers R Int J Cancer; 2011 Apr; 128(7):1747-50. PubMed ID: 20533286 [TBL] [Abstract][Full Text] [Related]
9. A20 inactivation in ocular adnexal MALT lymphoma. Bi Y; Zeng N; Chanudet E; Huang Y; Hamoudi RA; Liu H; Dong G; Watkins AJ; Ley SC; Zou L; Chen R; Zhu X; Du MQ Haematologica; 2012 Jun; 97(6):926-30. PubMed ID: 22207688 [TBL] [Abstract][Full Text] [Related]
11. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Rinaldi A; Mian M; Chigrinova E; Arcaini L; Bhagat G; Novak U; Rancoita PM; De Campos CP; Forconi F; Gascoyne RD; Facchetti F; Ponzoni M; Govi S; Ferreri AJ; Mollejo M; Piris MA; Baldini L; Soulier J; Thieblemont C; Canzonieri V; Gattei V; Marasca R; Franceschetti S; Gaidano G; Tucci A; Uccella S; Tibiletti MG; Dirnhofer S; Tripodo C; Doglioni C; Dalla Favera R; Cavalli F; Zucca E; Kwee I; Bertoni F Blood; 2011 Feb; 117(5):1595-604. PubMed ID: 21115979 [TBL] [Abstract][Full Text] [Related]
12. Frequent inactivation of A20 in B-cell lymphomas. Kato M; Sanada M; Kato I; Sato Y; Takita J; Takeuchi K; Niwa A; Chen Y; Nakazaki K; Nomoto J; Asakura Y; Muto S; Tamura A; Iio M; Akatsuka Y; Hayashi Y; Mori H; Igarashi T; Kurokawa M; Chiba S; Mori S; Ishikawa Y; Okamoto K; Tobinai K; Nakagama H; Nakahata T; Yoshino T; Kobayashi Y; Ogawa S Nature; 2009 Jun; 459(7247):712-6. PubMed ID: 19412163 [TBL] [Abstract][Full Text] [Related]
13. The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP. Jung H; Yoo HY; Lee SH; Shin S; Kim SC; Lee S; Joung JG; Nam JY; Ryu D; Yun JW; Choi JK; Ghosh A; Kim KK; Kim SJ; Kim WS; Park WY; Ko YH Oncotarget; 2017 Mar; 8(10):17038-17049. PubMed ID: 28152507 [TBL] [Abstract][Full Text] [Related]
14. Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren's syndrome. Nocturne G; Boudaoud S; Miceli-Richard C; Viengchareun S; Lazure T; Nititham J; Taylor KE; Ma A; Busato F; Melki J; Lessard CJ; Sivils KL; Dubost JJ; Hachulla E; Gottenberg JE; Lombès M; Tost J; Criswell LA; Mariette X Blood; 2013 Dec; 122(25):4068-76. PubMed ID: 24159176 [TBL] [Abstract][Full Text] [Related]
15. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. Clipson A; Wang M; de Leval L; Ashton-Key M; Wotherspoon A; Vassiliou G; Bolli N; Grove C; Moody S; Escudero-Ibarz L; Gundem G; Brugger K; Xue X; Mi E; Bench A; Scott M; Liu H; Follows G; Robles EF; Martinez-Climent JA; Oscier D; Watkins AJ; Du MQ Leukemia; 2015 May; 29(5):1177-85. PubMed ID: 25428260 [TBL] [Abstract][Full Text] [Related]
16. High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas. Vela V; Juskevicius D; Gerlach MM; Meyer P; Graber A; Cathomas G; Dirnhofer S; Tzankov A Hematol Oncol; 2020 Aug; 38(3):284-292. PubMed ID: 32012328 [TBL] [Abstract][Full Text] [Related]
17. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Compagno M; Lim WK; Grunn A; Nandula SV; Brahmachary M; Shen Q; Bertoni F; Ponzoni M; Scandurra M; Califano A; Bhagat G; Chadburn A; Dalla-Favera R; Pasqualucci L Nature; 2009 Jun; 459(7247):717-21. PubMed ID: 19412164 [TBL] [Abstract][Full Text] [Related]
18. A novel A20 (TNFAIP3) antibody (Ber-A20) can be used to detect unmutated A20 by immunohistology. Hirsch B; Grünbaum M; Wagner F; Bi Y; Lucka L; Du MQ; Stein H; Dürkop H Histopathology; 2012 May; 60(6B):E19-27. PubMed ID: 22393903 [TBL] [Abstract][Full Text] [Related]
19. BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas. Yan Q; Huang Y; Watkins AJ; Kocialkowski S; Zeng N; Hamoudi RA; Isaacson PG; de Leval L; Wotherspoon A; Du MQ Haematologica; 2012 Apr; 97(4):595-8. PubMed ID: 22102703 [TBL] [Abstract][Full Text] [Related]
20. Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary syndrome. Braun FC; Grabarczyk P; Möbs M; Braun FK; Eberle J; Beyer M; Sterry W; Busse F; Schröder J; Delin M; Przybylski GK; Schmidt CA Leukemia; 2011 Sep; 25(9):1494-501. PubMed ID: 21625233 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]